Tecentriq Gets a New Job
The US Food and Drug Administration has approved Tecentriq (atezolizumab) to treat advanced lung cancer.
Plus One for Lung Cancer Surgery
Surgery for patients with late-stage, non-small cell lung cancer (NSCLC) may increase survival, but many patients aren't having the procedure, a new study found.
Good News for Older Patients with Lung Cancer
Post-surgery survival rates for older patients with lung cancer may be improving, a new study found.
A New Job for Gilotrif
The US Food and Drug Administration has approved Gilotrif (afatinib) to treat squamous cell lung cancer.
A New Job for Xalkori
The US Food and Drug Administration (FDA) approved Xalkori (crizotinib) to treat patients with advanced non-small cell lung cancer (NSCLC) who have tumors with an ROS-1 gene alteration.
Is a PET Scan the Right Option for You?
For cancer survivors, vigilance is a key part of remaining cancer free. But new evidence suggests one cancer detection tool is being overused — and that isn’t helping anyone.
Cancer Meds in 2015: A Year in Review
This year was a big one for cancer treatment.
A New Option for ALK-Positive Lung Cancer
The U.S. Food and Drug Administration today approved Alecensa (alectinib) to treat people with advanced (metastatic) ALK-positive non-small cell lung cancer (NSCLC) whose disease has worsened after, or who could not tolerate treatment with, another therapy called Xalkori (crizotinib).
FDA OKs Lung Cancer Rx Portrazza
The U.S. Food and Drug Administration today approved Portrazza (necitumumab) in combination with two forms of chemotherapy to treat patients with advanced (metastatic) squamous non-small cell lung cancer (NSCLC) who have not previously received medication specifically for treating their advanced lung cancer.
FDA Approves New Lung Cancer Rx
On November 13, 2015, the U. S. Food and Drug Administration granted accelerated approval to osimertinib (TAGRISSO) once daily tablets, AstraZeneca Pharmaceuticals LP, for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, who have progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy.